At the end of the latest market close, ACADIA Pharmaceuticals Inc. (ACAD) was valued at $26.57. In that particular session, Stock kicked-off at the price of $26.73 while reaching the peak value of $27.06 and lowest value recorded on the day was $25.62. The stock current value is $26.13.
Recently in News on June 9, 2021, LAWSUITS FILED AGAINST CAN, ACAD and PCT – Jakubowitz Law Pursues Shareholders Claims. Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below. You can read further details here
ACADIA Pharmaceuticals Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $55.85 on 01/08/21, with the lowest value was $19.20 for the same time period, recorded on 05/05/21.
ACADIA Pharmaceuticals Inc. (ACAD) full year performance was -44.98%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, ACADIA Pharmaceuticals Inc. shares are logging -55.50% during the 52-week period from high price, and 36.09% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $19.20 and $58.72.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1763399 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the ACADIA Pharmaceuticals Inc. (ACAD) recorded performance in the market was -51.12%, having the revenues showcasing -2.83% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 4.12B, as it employees total of 640 workers.
ACADIA Pharmaceuticals Inc. (ACAD) in the eye of market guru’s
During the last month, 12 analysts gave the ACADIA Pharmaceuticals Inc. a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 6 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 32.39, with a change in the price was noted -28.33. In a similar fashion, ACADIA Pharmaceuticals Inc. posted a movement of -52.02% for the period of last 100 days, recording 2,139,192 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ACAD is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
ACADIA Pharmaceuticals Inc. (ACAD): Stocks Technical analysis and Trends
Raw Stochastic average of ACADIA Pharmaceuticals Inc. in the period of last 50 days is set at 88.17%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 85.56%. In the last 20 days, the company’s Stochastic %K was 91.06% and its Stochastic %D was recorded 92.82%.
If we look into the earlier routines of ACADIA Pharmaceuticals Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -51.12%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -51.05%, alongside a downfall of -44.98% for the period of the last 12 months. The shares increased approximately by 15.52% in the 7-day charts and went down by 24.31% in the period of the last 30 days. Common stock shares were lifted by -2.83% during last recorded quarter.